32 results about "Corneal endothelial cell" patented technology

The invention provides application of taurochenodeoxycholic acid in preparation of a medicine for preventing and / or treating Fuchs corneal endothelial dystrophy, and particularly belongs to the technical field of medicine preparation. The invention provides an application of taurochenodeoxycholic acid in preparation of a medicine for preventing and / or treating Fuchs corneal endothelial dystrophy. Test results show that taurochenodeoxycholic acid can realize prevention and / or treatment of corneal endothelial cell injury caused by UVA; the number reduction, activity reduction, oxidative stress, ROS level rise and mitochondrial membrane potential drop of corneal endothelial cells caused by UVA are relieved; mitochondrial biological energy deficiency caused by UVA is relieved; and the prevention and / or treatment of the Fuchs corneal endothelial dystrophy are / is realized by activating a Ca < 2 + > signal channel.

The present invention provides a method for determining the quality of cultured corneal endothelial cells (CECs) comprising measuring in or on a cultured CEC a level of expression of the genes Thrombospondin-2 (THBS2) and / or Vitelline Membrane Outer Layer 1 Homolog (VMO1), and determining that the quality of said cultured CEC is non-therapy-grade if said measured level of expression corresponds to a THBS2+ and / or VMO1+ expression profile.

The present invention aims to provide a cell inoculum and a cell transplantation substrate which can be subcultured without causing cell transformation and can effectively implant cells. An inoculum and a transplantation substrate containing a phenolphthalein derivative for facilitating implantation of cultured corneal endothelial cells or corneal endothelial replacement cells. The inoculum and the transplantation substrate can facilitate adhesion of cells during subculture and implantation of cells during transplantation.

The present disclosure provides a method for cryopreserving corneal endothelial cells and / or corneal endothelial-like cells, and a freezing prepartaion for corneal endothelial cells and / or corneal endothelial-like cells. The present disclosure provides a method for preserving corneal endothelial cells and / or corneal endothelial-like cells, wherein the method includes: a freezing step for freezing unfrozen corneal endothelial cells and / or corneal endothelial-like cells, the freezing step including at least one stage in which the temperature is reduced at a rate of less than 1°C / min when the temperature is changed from the unfrozen temperature to the freezing target temperature; and, if necessary, a step for maintaining the corneal endothelial cells and / or the corneal endothelial-like cells in a frozen state.

Congenital hereditary endothelial dystrophy (CHED) is an autosomal recessive condition affecting the corneal endothelial cells, which function to maintain corneal clarity. Currently there is no highly efficacious treatment available for CHED caused by SLC4A11 gene mutations. The invention disclosed herein includes mammalian vectors for use in the treatment of Congenital hereditary endothelial dystrophy and methods for using such vectors.

The present application relates to the technical field of medical data processing, in particular to a cataract ultrasonic emulsification postoperative corneal rehabilitation evaluation system based on deep learning. The system comprises an image acquisition module for acquiring postoperative corneal endothelial cell images of a person; a first abnormality analysis module for extracting abnormal corneal regions in the corneal endothelial cell images; a second abnormality analysis module for screening out suspected mechanical damage regions from the abnormal corneal regions; a region segmentation module for segmenting the suspected mechanical damage regions into suspected damage sub-regions; a region division module for determining the division parameters of the suspected damage sub-regions belonging to mechanical damage; based on the pixel number, area and corresponding division parameters in the suspected damage sub-regions, determining the rehabilitation degree, and dividing the suspected damage sub-regions into mechanical damage regions and hyperglycemia damage regions. The present application improves the accuracy of segmentation of mechanical damage regions and hyperglycemia damage regions.

The present invention relates to the use of corneal cell-derived mitochondria for the prevention or treatment of corneal damage or corneal endothelial cell diseases. It has been confirmed that mitochondria isolated from corneal endothelial cells differentiated from induced pluripotent stem cells (iPSCs) of the present invention alleviate the inflammatory response of corneal endothelial cells in an inflammatory environment, restore the integrity and function of corneal endothelial cells, and, when delivered into heterologous primary corneal endothelial cells, suppress inflammatory responses, particularly inflammation caused by physical damage, and promote the regeneration of corneal endothelial cells. Therefore, mitochondria possessing such effects can overcome the tumorigenic limitations of conventional stem cell therapies, and due to their ease of production and minimal regulatory requirements, they offer excellent cost-effectiveness and broad applicability.

1. Name of the product in this design: Corneal endothelial cell counter. 2. Purpose of this design: This design is used as an ophthalmic device for evaluating the density, morphology and function of corneal endothelial cells. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: a 3D model.

Human embryonic stem cell (hESC)- and induced pluripotent stem cell (iPSC)-derived clinical-grade corneal endothelial cells (CECs) generation and cryopreservation through the neural crest cell (NCC) lineage using peripheral blood as a donor source and hESCs maximizes the availability of these vital cells for treating the corneal endothelial disease as an alternative to donor corneas for corneal endothelium (CE) transplantations and other applications.

The present invention refers to an in vitro or ex vivo method for reversing and / or reducing and / or inhibiting the endothelial to mesenchymal transition (EnMT) process in corneal endothelial cells, preferably in primary and / or human corneal endothelial cells, more preferably primary human corneal endothelial cells (HCEnCs), said method comprising the step of incubating said cells with at least one inhibitor of glycogen synthase kinase 3 (GSK-3).

To provide a method for producing a cultured human corneal endothelial cell useful for an extremely long period of time for improving corneal opacity and hydration edema of a patient with corneal endothelial dysfunction.SOLUTION: A method for producing a human functional corneal endothelial cell capable of inducing a human corneal function when injected into an anterior chamber of a human eye, comprising (b) a step of proliferating and / or differentiating / maturing a corneal endothelial progenitor cell under a culture condition capable of minimizing culture stress such as proliferation stress.SELECTED DRAWING: None

The application provides an application of alpha-ketoglutaric acid in improving corneal endothelial injury and dysfunction, and belongs to the technical field of biological medicine. The application finds that, as a key metabolic intermediate in the tricarboxylic acid cycle, alpha-ketoglutaric acid can significantly reduce corneal endothelial cell injury and dysfunction induced by various causes such as high glucose, genetic defects, high intraocular pressure and surgical trauma by improving mitochondrial energy metabolism, reducing oxidative stress, stabilizing mitochondrial structure and membrane potential. Experiments prove that alpha-ketoglutaric acid can be used in the form of local administration such as eye drops, anterior chamber perfusion, systemic oral administration or combined administration, effectively reduces corneal edema, reduces central corneal thickness, shortens the recovery time of corneal transparency, and has a clear protection and repair effect on diabetic-related corneal endothelial lesions, Fuchs corneal endothelial dystrophy, glaucoma high intraocular pressure injury and intraocular surgery-related endothelial injury.

The present invention complete a technique of treating a corneal disorder or disease by infusion into an anterior chamber of human eyes. Specifically, the present invention based on the findings discovered that cultured human corneal endothelial cells are comprised of a plurality of subpopulations, most of them are not suitable for infusion into patients. The above-described subject was overcome by providing, as a medicament, functionally high grade quality of cells having the function of mature differentiated human corneal endothelial cells which is a specific subpopulation and characterized by their biochemical and functional phenotypes. The present invention provides such a functional mature differentiated corneal endothelial cells, medicament comprising, the same, and manufacturing method, quality control and techniques related thereto.

Provided are compositions comprising aggregates of corneal endothelial cells (CECs) and methods administering said aggregates to patients for the treatment of corneal endothelial disease.

Provided are compositions comprising aggregates of corneal endothelial cells (CECs) and methods administering said aggregates to patients for the treatment of corneal endothelial disease.

The invention provides application of a deep eutectic solvent in preparation of a medicine for promoting adeno-associated virus anterior chamber transfection, and belongs to the technical field of medicine preparation. The invention relates to an application of a deep eutectic solvent in preparation of drugs for promoting adeno-associated virus or genetically modified adeno-associated virus transfection. The deep eutectic solvent is prepared from choline chloride and fructose in a molar ratio of 2: 1. The deep eutectic solvent (DES) has moderate viscosity and approximately clear and transparent appearance, can stay in an anterior chamber for a certain time without blocking chamber corners, has the advantages of low toxicity, biodegradability, simplicity and convenience in synthesis and the like, and can be used as a delivery carrier of an adeno-associated virus (AAV). The DES is injected into the animal model in the anterior chamber, the DES cannot cause changes of corneal transparency, corneal thickness, corneal barrier function, pump function and corneal endothelial cell morphology, the safety is good, the anterior chamber AAV transfection efficiency can be improved, and outflow of AAV along with aqueous humor circulation and immunogenicity are reduced.

Cryopreservation of endothelial cell monolayers is one of the major challenges in the cryopreservation of complex tissues. Human umbilical vein endothelial cells (HUVECs) in suspension are available commercially and recently their post-thaw cell membrane integrity was significantly improved by cryopreservation in 5% dimethyl sulfoxide (DMSO) and 6% hydroxyethyl starch (HES). However, cryopreservation of cells in monolayers has been elusive. The exact mechanisms of damage during cell monolayer cryopreservation are still under investigation. Here, we show that a combination of different factors contribute to significant progress in cryopreservation of cell monolayers. The addition of 2% chondroitin sulfate to 5% DMSO and 6% HES and cooling at 0.2 or 1° C. / min led to high membrane integrity (97.3±3.2%) immediately after thaw when HUVECs were cultured on a substrate with a coefficient of thermal expansion similar to that of ice. The optimized cryopreservation protocol was applied to monolayers of primary porcine corneal endothelial cells, and resulted in high post-thaw viability (95.9±3.7% membrane integrity) with metabolic activity 12 hours post-thaw comparable to unfrozen control.

A method for preparing an exosome includes: cultivating corneal stromal keratocytes (CSKs) in a culture medium containing vitamin C, so as to obtain a cell culture of the CSKs containing the exosome; and subjecting the cell culture to an isolation treatment, so as to obtain the exosome. An exosome prepared by the aforesaid method, and methods for promoting proliferation of corneal endothelial cells and improving wound healing in a corneal endothelium using the exosome are also provided.

The invention discloses a method for promoting differentiation of cranial nerve crest cells into corneal endothelial cells. According to the method, a culture medium with definite chemical components is used for inducing differentiation of the nerve crest cells into the corneal endothelial cells. The method provided by the invention has the advantages of high induced differentiation efficiency, strong stability, clear culture system components, high safety and the like, and is suitable for large-scale induced differentiation culture of corneal endothelial cells; and the prepared corneal endothelial cell is highly consistent with the primary corneal endothelial cell in the aspects of contact inhibition, ion transport, metabolic function and the like, and has huge market value and wide application prospect.

Human corneal endothelial cells and / or human corneal endothelial precursor cells are preserved with a high survival rate of these cells being maintained, and the occurrence rate of contaminated cells in post-preservation culturing is suppressed. A storage method of human corneal endothelial cells and / or human corneal endothelial precursor cells is characterized in that human corneal endothelial cells and / or human corneal endothelial precursor cells that have been cultured using a culture medium that contains a ROCK inhibitor, and in which the content of epidermal growth factor (EGF) is less than a concentration that will cause a transformation are harvested at a timing when any one of or a plurality of the conditions (a)˜(d) have been met, and are placed in a suspension state and then preserved.

The present invention provides cell trait assay techniques which identify cultured human corneal endothelial cells that, in a clinical trial, have been confirmed to express early-stage clinical effects and provide clinical effects that are stable in the long term. Provided is a method for producing functional human corneal endothelial cells which can bring about human corneal function when injected into the anterior chamber of a human eye, said method including a step for growing and / or differentiating / maturing corneal endothelium precursor cells under culturing conditions that can minimize culturing stress such as growth stress. Also provided are functional human corneal endothelial cells which have been found to express a functional protein leading to corneal endothelium (cell) functional characteristics that improve corneal clouding and hydration swelling, and, as a result, sustainably maintain corneal endothelium tissue cell density in the long term and lead to eyesight improvement, or in which proteins that inhibit such corneal endothelium (cell) functional characteristics are have not been elicited or are reduced.

The present disclosure provides: a method for washing corneal endothelial cells; and a method for producing a corneal endothelial cell preparation. In one aspect, the present disclosure provides a method for producing a corneal endothelial cell preparation, the method comprising a step for washing a corneal endothelial cell or a corneal endothelium-like cell with a solution containing about 0.01% by weight to about 10% by weight of a protein and a step for mixing the corneal endothelial cell or the corneal endothelium-like cell with a composition for preparation production use to produce a corneal endothelial preparation, in which the protein is selected from the group consisting of human serum albumin, casein, lactoferrin, ovalbumin, and combinations thereof.

The invention provides a therapeutic effect of a carrier for supplementing wild type SLC4A11 gene and / or protein on corneal endothelial cell dysfunction, and belongs to the technical field of gene drugs. The invention provides an application of a reagent for supplementing wild type SLC4A11 gene and / or protein in preparation of a medicine for treating corneal endothelial cell dysfunction, and provides a gene therapy technical scheme for targeting corneal endothelial cells by taking SLC4A11 related CHED as a representative disease model. The invention provides a gene therapy vector for corneal endothelial cell dysfunction, the gene therapy vector comprises an AAV vector carrying a wild type SLC4A11 gene, the corneal endothelial cell dysfunction is treated by supplementing the wild type SLC4A11 gene and / or protein, efficient, specific and long-term expression of the exogenous SLC4A11 gene in corneal endothelial cells is realized, and the corneal endothelial cell dysfunction is obtained. Therefore, the pump function of endothelial cells is recovered, corneal edema is reduced, and transparency is improved.

One aspect of the present invention relates to a method for preparing a high-purity corneal endothelial cell population. The method for preparing a high-purity corneal endothelial cell population according to one aspect can not only increase the efficiency of corneal endothelial cell differentiation from stem cells, but can also improve the function, survival rate, and purity of corneal endothelial cells directly differentiated from stem cells.

Provided are methods of treating or preventing corneal endothelial disease. The present disclosure relates to corneal endothelial cell compositions comprising cultured human corneal endothelial cells and a Rho-associated, coiled-coil containing protein kinase inhibitor, and uses of the compositions for the treatment of corneal endothelial diseases, including bullous keratopathy, corneal edema, corneal leukoma, corneal endothelial inflammation, and corneal dystrophy.

The invention relates to the technical field of medical data processing, in particular to a cataract ultrasonic emulsification postoperative cornea rehabilitation evaluation system based on deep learning. The system comprises an image acquisition module used for acquiring a corneal endothelial cell image of a postoperative person; the first anomaly analysis module is used for extracting an abnormal cornea region in the cornea endothelial cell image; the second anomaly analysis module is used for screening a suspected mechanical injury area from the abnormal cornea area; the region segmentation module is used for segmenting the suspected mechanical damage region into suspected damage sub-regions; the region division module is used for determining distinguishing parameters of the suspected damage sub-regions belonging to the mechanical damage; based on the pixel number, the area and the corresponding distinguishing parameters in the suspected injury sub-region, the rehabilitation degree is determined, and the suspected injury sub-region is divided into a mechanical injury region and a hyperglycemia injury region. According to the method, the segmentation accuracy of the mechanical injury area and the hyperglycemia injury area is improved.

A technique for treating cornea is provided. More specifically, the present invention is an agent for treating or preventing a state of corneal endothelial disease, said agent comprising at least one factor selected from the group consisting of laminin and fragments thereof, whereby said problem is solved by also providing a technique characterized in that the agent is administered together with corneal endothelial cells. In particular, the present invention may comprise laminin 511 ([alpha] 5 [beta] 1 [gamma] 1), laminin 521 ([alpha] 5 [beta] 2 [gamma] 1), or fragments of these.